TY - JOUR
T1 - Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma
T2 - Immunohistochemical and RT-PCR studies
AU - Akahira, J.
AU - Inoue, T.
AU - Suzuki, T.
AU - Ito, K.
AU - Konno, R.
AU - Sato, S.
AU - Moriya, T.
AU - Okamura, K.
AU - Yajima, A.
AU - Sasano, H.
N1 - Funding Information:
This work is in part supported by the grant-in-aid for Cancer Research 7–1 from the Ministry of Health and Welfare, Japan, a grant-in-aid for scientific research area on priority area (A-11137301) from the Ministry of Education, Science and Culture, Japan, a grant-in-aid for Scientific Research (B-11470047) from Japan Society for the Promotion of Science and a grant from The Naitou Foundation and Suzuken Memorial Foundation. We appreciate Dr Toru Tase and Dr Hiroo Tateno for their cooperation in retrieving the specimens of ovarian carcinoma tissues at the Miyagi Prefectural Cancer center, Natori, Japan. We also appreciate Ms Keiko Abe and Ms Ayako Kusumi for their technical assistance. We would like to acknowledge the editing of the manuscript by Mr Andrew D Darnel, Department of Pathology, Tohoku University School of Medicine, Sendai, Japan.
PY - 2000
Y1 - 2000
N2 - Human epithelial ovarian carcinoma is well-known as a sex steroid-dependent neoplasm, but the possible biological significance of progesterone receptor (PR) in this cancer remains controversial. Recently, two isoforms of human PR, PRA and PRB, have been characterized and different functional characteristics have been reported for these two isoforms. We therefore examined immunohistochemistry (107 cases) and reverse transcription-polymerase chain reaction (RT-PCR) (16 cases) for PRA, PRB, and oestrogen receptor-a (ER-a). Labeling indices (LI) for PRA and PRB were 2.4 and 43.6, respectively, and the difference was statistically significant. PRB LI, but not PRA LI, as well as performance status, stage, and residual tumour turned out to be independent prognostic factors following multivariate analysis. There was also a significant correlation between ER-a LI and PRB LI (r = 0.595, P < 0.0001), suggestive of a possible interaction between these two receptors. RT-PCR also detected the expression of PR isoform transcripts in the same pattern as was observed with immunohistochemistry. Results of these studies indicate that PRA and PRB both mediate distinct pathways of progesterone action in ovarian carcinoma. Moreover, it is important to examine PRB LI as a prognostic factor in the cases of human epithelial ovarian carcinoma. (C) 2000 Cancer Research Campaign.
AB - Human epithelial ovarian carcinoma is well-known as a sex steroid-dependent neoplasm, but the possible biological significance of progesterone receptor (PR) in this cancer remains controversial. Recently, two isoforms of human PR, PRA and PRB, have been characterized and different functional characteristics have been reported for these two isoforms. We therefore examined immunohistochemistry (107 cases) and reverse transcription-polymerase chain reaction (RT-PCR) (16 cases) for PRA, PRB, and oestrogen receptor-a (ER-a). Labeling indices (LI) for PRA and PRB were 2.4 and 43.6, respectively, and the difference was statistically significant. PRB LI, but not PRA LI, as well as performance status, stage, and residual tumour turned out to be independent prognostic factors following multivariate analysis. There was also a significant correlation between ER-a LI and PRB LI (r = 0.595, P < 0.0001), suggestive of a possible interaction between these two receptors. RT-PCR also detected the expression of PR isoform transcripts in the same pattern as was observed with immunohistochemistry. Results of these studies indicate that PRA and PRB both mediate distinct pathways of progesterone action in ovarian carcinoma. Moreover, it is important to examine PRB LI as a prognostic factor in the cases of human epithelial ovarian carcinoma. (C) 2000 Cancer Research Campaign.
KW - Immunohistochemistry
KW - Ovarian cancer
KW - PRA
KW - PRB
KW - Progesterone receptor
KW - RT-PCR
UR - http://www.scopus.com/inward/record.url?scp=0033665373&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033665373&partnerID=8YFLogxK
U2 - 10.1054/bjoc.2000.1463
DO - 10.1054/bjoc.2000.1463
M3 - Article
C2 - 11076658
AN - SCOPUS:0033665373
VL - 83
SP - 1488
EP - 1494
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 11
ER -